Comment on

• Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.

  Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O'Shaughnessy J, Gradishar W, Schmid P, Winer E, Kelly C, Nanda R, Gucalp A, Awada A, Garcia-Estevez L, Trudeau ME, Steinberg J, Uppal H, Tudor IC, Peterson A, Cortes J. Traina TA, et al. J Clin Oncol. 2018 Mar 20;36(9):884-890. doi: 10.1200/JCO.2016.71.3495. Epub 2018 Jan 26. J Clin Oncol. 2018. PMID: 29373071 Free PMC article. Clinical Trial.
• Is the Clinical Benefit Rate at Sixteen Weeks a Reliable End Point?

  Shohdy KS, Kassem L, Mangalik A. Shohdy KS, et al. J Clin Oncol. 2018 Aug 10;36(23):2457-2458. doi: 10.1200/JCO.2018.78.5139. Epub 2018 May 30. J Clin Oncol. 2018. PMID: 29847293 No abstract available.